Pembrolizumab is approved in metastatic nonsquamous NSCLC patients without EGFR or ALK genomic tumor aberrations, irrespective of PD-L1 expression, as a first-line treatment in combination with pemetrexed and carboplatin on the basis of phase I/II KEYNOTE-021 study [114]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.